Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib for NF1-associated plexiform neurofibromas and optic pathway gliomas
ACTRN12620001229965Phase 2Completed
- Sponsor
- Australian Pharmaceutical Industries
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of trametinib in plexiform neurofibroma (PN) and optic nerve glioma (OPG) (3 cohorts), sponsored by Australian Pharmaceutical Industries. Started Mar 2021; status: completed.
02
Drugs
trametinib
03
Conditions
plexiform neurofibroma (PN)optic nerve glioma (OPG)
Beyond the preview
Go deeper on ACTRN12620001229965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001229965.